Clinical Trial Update: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the immune response and safety of an RSV vaccine in adults 50 years and older, given alone or together with a COVID-19 mRNA vaccine; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• RSV vaccine (GlaxoSmithKline)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2025-12-26